Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi

In asking the Supreme Court to review its PCSK9 patent case, Amgen says the federal appeals court has created its own legal standard for patent cases. (

Amgen made an aggressive legal bid to push Sanofi and Regeneron's rival PCSK9 drug off the market when the two were first duking it out in 2015. It didn't work—but Amgen hasn't given up. It's aiming to take the battle to the U.S. Supreme Court instead.

After falling short with its arguments in federal appeals court, Amgen is asking the Supreme Court to strike up a review of the case. Amgen claimed Sanofi and Regeneron stepped on its PCSK9 patents and initially won an injunction against their drug Praluent.

In a petition for a writ of certiorari, Amgen now argues that the U.S. Court of Appeals for the Federal Circuit incorrectly interpreted and ruled on patent law. The company says the court has created its own standard that has resulted in “jurisprudential anarchy.” Amgen markets the PSCK9 cholesterol drug Repatha in a head-to-head battle with Praluent; both products have fallen short of expectations, mostly because payers limited access to the high-priced drugs.

Amgen's filing comes after years of legal back-and-forth between the drugmakers. Amgen sued Sanofi and Regeneron in 2014, and in early 2016, a jury upheld the Amgen patents and the judge in the case granted an injunction against Praluent sales. Sanofi and Regeneron won a stay of the injunction, but analysts believed Sanofi and Regeneron might be forced to pay Amgen royalties.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

An October 2017 decision changed all that. The Federal Circuit ruled that the jury was given incorrect instructions, threw out the injunction and ordered a new trial.

RELATED: Court tosses Praluent ban, gives Sanofi and Regeneron a new trial in Amgen patent battle 

In its Supreme Court filing, Amgen says the appeals court’s approach to patent disputes “defies the statute and precedent.” The company argues the court has created its own “possession” standard that doesn’t fit with the Patent Act, and that the court has created new “sub-tests” to implement its standard. Under the standard, the written description for a patent must prove the inventor possessed the invention on the filing date, according to Amgen’s filing. 

From Amgen’s perspective, the “ever-shifting demands of those sub-formulations have left innovators no way of predicting what disclosures will be sufficient” to protect their patents. 

Since the appeals court decision, Sanofi and Regeneron have been aggressive in promoting Praluent. In March, the partners presented data at the American College of Cardiology showing the drug cut death risks by 29% in the most vulnerable patients. At the same time, the companies said they would discount the med to within a price range of $4,460 to $7,975 per year suggested by cost watchdog ICER.  

Two months later, the partners struck an exclusive deal with leading pharmacy benefit manager Express Scripts, agreeing to lower Praluent’s price to win a spot on the PBM’s national preferred formulary. 

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.